Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 24th 2015

Another First for Nivolumab: Approved as Frontline for BRaf Wild Type Melanoma

Surabhi Dangi-Garimella, PhD

The approval follows 5 months after Bristol-Myers Squibb submitted phase 3 results of the Checkmate-066 trial for FDA review.

November 23rd 2015

Nivolumab Approved for Third Indication: Advanced Renal Cell Carcinoma

Surabhi Dangi-Garimella, PhD

Two months after being granted a Breakthrough Therapy designation by the FDA for metastatic renal cell carcinoma (mRCC), nivolumab was today approved by regulators for treating mRCC patients who have failed a certain type of prior therapy.

November 23rd 2015

Decade-Long Screening Efforts Bear Fruit for CRC Screening in New York City

Surabhi Dangi-Garimella, PhD

A state-led program, initiated in 2003, has nearly doubled screening colonoscopy rates in New York City and also eliminated racial and ethnic disparities in the process.

November 22nd 2015

Staying Focused on the Cancer Patient, Amid Rising Drug Costs and New Payment Models

Giving cancer patients what they want and need is the goal, but getting there isn't easy, according to healthcare experts who took part in Patient-Centered Oncology Care 2015, presented November 19-20, 2015, by The American Journal of Managed Care. Drug costs demand difficult conversations about value, and changes in the law require oncologists to learn whole new ways to be paid.

November 21st 2015

As Prospect of Risk for Doctors Looms, Cost Conversation Shifts in Cancer Care

Mary K. Caffrey

Three years after Memorial Sloan Kettering Cancer Center refused to add Zaltrap to its formulary due to cost, value is part of the national conversation in cancer care. The new question is what will happen when physicians assume risk.

November 21st 2015

Dr Scott Gottlieb Worries About More FDA Regulation in Diagnostic Testing

If the FDA steps in to regulate laboratory-developed tests, it will slow down innovation, add costs to the development of the product, and likely decrease the number of tests that come out, but the public health benefits of increased oversight might be worth it, said Scott Gottlieb, MD, resident fellow at the American Enterprise Institute.

November 21st 2015

Dr Peter Bach Examines the Problems of the 340B Drug Pricing Program

While the 340B Drug Pricing Program was designed to help facilities that take care of impoverished patients with low-cost drugs, what the program has morphed into is almost the opposite of what it was intended to do, said Peter Bach, MD, MPP, director of Memorial Sloan Kettering's Center for Health Policy and Outcomes.

November 21st 2015

Are PBMs the Answer to Managing the High Cost in Oncology Care?

Surabhi Dangi-Garimella, PhD

A pharmacist who engages in formulary decisions, a medical director for population management for a private health exchange, and an innovations leader at a pharmacy benefit manager, took to the podium at the Patient-Centered Oncology Care meeting on November 20, 2015, to discuss cost-saving strategies in oncology and whether benefit managers can play a role in reining-in some of these costs.

November 20th 2015

End-of-Life and Palliative Care to Be Discussed During AJMC's November 24 Tweetchat

During a tweetchat on November 24 at 3:30 pm EST, Amy Berman, RN, BS, and Judith R. Peres, LCSW-C, will discuss patient-centered care, palliative care, and end-of-life care.

November 20th 2015

Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently

While the FDA could regulate diagnostic tests the way they are in Europe-through simple verification that the test is accurate-the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.

November 20th 2015

Dr Julie Vose Weighs in on Value Calculators, MACRA

Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology (ASCO), and keynote speaker at this year's Patient-Centered Oncology Care meeting, discusses addressing cost of care, using value calculators, and the Medicare Access and CHIP Reauthorization Act.

November 20th 2015

What We're Reading: CMS Wants to Penalize Doctors for Prostate Tests

AJMC Staff

What we're reading, November 20, 2015: CMS wants to penalize doctors for ordering routine prostate-cancer screening tests; lawmakers, patients, and advocates call for head of Drug Enforcement Agency to be fired; and specialty drug costs exceed household incomes.

November 20th 2015

FDA Seems Poised to Regulate LDTs in Oncology, but Is That a Good Thing?

Mary K. Caffrey

A panel that discussed the prospect of FDA regulation of diagnostic tests in oncology helped open Patient-Centered Oncology Care November 19, 2015, in Baltimore, Maryland.

November 20th 2015

ASCO President Reviews Post-SGR Challenges for Oncologists

Surabhi Dangi-Garimella, PhD

At the Patient-Centered Oncology Care 2015 meeting, held November 19-20, 2015, in Baltimore, Maryland, keynote speaker Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology provided perspectives on the challenges faced by oncologists as the healthcare system transitions to define and incorporate value in the care delivered.

November 19th 2015

Addressing the Elephants in the Room: Healing Through Discussion

Samantha Eisenstein Watson, MBA

Collaboration between organizations serving the young adult cancer population benefits all involved

November 19th 2015

Absence of Prescription Coverage Could Prove Catastrophic in Cancer, Study Shows

Surabhi Dangi-Garimella, PhD

Eligibility for prescription coverage and family income significantly influenced women's decisions to continue hormonal therapy and prevent recurrence of breast cancer, the authors found.

November 18th 2015

ASCO Responds to CMS on Reimbursement Changes Under MACRA

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology has made public its detailed guidance to CMS, supporting implementation of physician-focused and other alternative payment models under MACRA.

November 18th 2015

Joy Larsen Haidle on How the Genetic Testing Landscape Has Changed

After the Supreme Court struck down gene patents, not only is more genetic testing is being offered, but the technology of the test has expanded to the benefit of patients, said Joy Larsen Haidle, MS, CGC, president of the National Society of Genetic Counselors.

November 18th 2015

Surabhi Dangi-Garimella, PhD

This is the company's third biosimilar Biologics License Application in the United States.

November 17th 2015

Tagrisso Approved, but Can Patients With EGFR-Mutant NSCLC Afford It?

Surabhi Dangi-Garimella, PhD

The drug is estimated to cost close to $13,000 per month.

November 17th 2015

FDA Regulation of LDTs: A Report Justifies the Need for It

Surabhi Dangi-Garimella, PhD

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

November 16th 2015

Daratumumab Approval Yields the First Monoclonal Antibody, and Another Option, in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The drug was approved based on results of 2 open-label studies that showed reduction in tumor burden of patients who had previously received multiple lines of therapy.

November 16th 2015

Should We Trust Screening Age Recommendations in Cancer?

Surabhi Dangi-Garimella, PhD

When to screen and how to screen remain controversial issues in prostate cancer.

November 14th 2015

This Week in Managed Care: November 14, 2015

This week in managed care the top stories include pivotal results from the SPRINT study on blood pressure, an analysis on how states successfully enrolled consumers in the insurance marketplace, and experts discuss value-based care.

November 13th 2015

Creating a Supportive Environment Through the Use of Palliative Care

Laura Joszt, MA

Panelist discuss early referral to palliative care, enduring misconceptions, culture considerations, and more at the Fall Managed Care Forum 2015.

November 12th 2015

Smoking Rates Declining but Disparities Evident: CDC Report

Surabhi Dangi-Garimella, PhD

According to the CDC, while smoking rates are seeing a steady decline, rates for uninsured and adults on Medicaid are more than twice those for adults with private health insurance.

November 12th 2015

Learning From Your Daughters About Cancer Prevention

Surabhi Dangi-Garimella, PhD

A study in The European Journal of Public Health finds conversation on preventive vaccination against HPV can motivate participation in preventive screening for cervical cancer.

November 11th 2015

Oral Contraceptives Can Improve Outcomes in Ovarian Cancer

Surabhi Dangi-Garimella, PhD

A retrospective study conducted at the Mayo Clinic found improved OS and PFS in ovarian cancer patients with a history of oral contraceptive use.

November 11th 2015

Narrow Network and Insolvent Exchange Plan Leaves Cancer Patients Scampering for Options

Surabhi Dangi-Garimella, PhD

A forced closing of Health Republic Insurance of New York has left many in need of immediate coverage.

November 10th 2015

Dr Crystal S. Denlinger Discusses Potential Cardiotoxicity Concerns for Cancer Survivors

Historically cancer survivorship programs have not emphasized cardiac follow-up and there is not a lot of long-term data on cardiac toxicity in patients who received certain drugs, but that is changing as patients live longer and fuller lives after treatment, explained Crystal S. Denlinger, MD, from the Fox Chase Cancer Center in Philadelphia.

...

114 115 116 117 118 119 120 121 122

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions